HMGA2 sustains self-renewal and invasiveness of glioma-initiating cells

Xiaoling Zhong; Xuan Liu; Yamu Li; Man Cheng; Wen Wang; Kuan Tian; Lili Mu; Tao Zeng; Ying Liu; Xiaobing Jiang; Luyang Yu; Liang Gao; Yan Zhou

doi:10.18632/oncotarget.9744

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HMGA2 sustains self-renewal and invasiveness of glioma-initiating cells

Xiaoling Zhong _, Xuan Liu, Yamu Li, Man Cheng, Wen Wang, Kuan Tian, Lili Mu, Tao Zeng, Ying Liu, Xiaobing Jiang, Luyang Yu, Liang Gao and Yan Zhou

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:44365-44380. https://doi.org/10.18632/oncotarget.9744

Metrics: PDF 2069 views | HTML 3011 views | ?

Abstract

Xiaoling Zhong1, Xuan Liu1, Yamu Li1, Man Cheng1, Wen Wang1, Kuan Tian1, Lili Mu1, Tao Zeng2, Ying Liu1, Xiaobing Jiang3, Luyang Yu4, Liang Gao2, Yan Zhou1

1Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences at Wuhan University, Wuhan 430072, China

2Department of Neurosurgery, The Tenth Affiliated Hospital, Tongji University, Shanghai 200072, China

3Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

4College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China

Correspondence to:

Liang Gao, email: [email protected]

Yan Zhou, email: [email protected]

Keywords: glioma, cancer stem cell, pericyte, self-renewal, cell invasion

Received: December 17, 2015 Accepted: May 20, 2016 Published: May 31, 2016

ABSTRACT

Glioblastoma multiforme (GBM) is the most common type of brain tumors with dismal outcomes. The mesenchymal phenotype is the hallmark of tumor aggressiveness in GBMs. Perivascular smooth muscle cells (pericytes) are essential in homeostasis of normal and glioma tissues. Here we found HMGA2, an architectural transcription factor that promotes mesenchymal phenotypes in a number of solid tumors, is highly expressed in mesenchymal subtype of GBMs and labels both glioma pericytes and glioma-initiating cells (GICs). Accordingly, depletion of HMGA2 in GICs resulted in compromised self-renewal and tumorigenic capability, as well as undermined mesenchymal or pericyte differentiation. We further showed HMGA2 allows expressions of FOXM1 and PLAU to maintain GIC propagation, gliomagenesis and aggressiveness both in vitro and in vivo. Therefore, suppressing HMGA2-mediated GIC self-renewal and invasiveness might be a promising means to treat GBMs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9744

Publication Alerts

Research Papers:

HMGA2 sustains self-renewal and invasiveness of glioma-initiating cells

Abstract